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of calcium used in phosphate-binding agents, and avoid-
ance of calcium altogether in patients with hypercalcemia,
overly suppressed intact parathyroid hormone, or with
severe arterial or other soft tissue calcification.5,6 Since the
guidelines’ publication cut-off date (2002), more data have
emerged against calcium, including a direct link between
the use of calcium-based binders and increase in calcifica-
tion,7,8 although not the dose of calcium in one of the
studies.8 Now two outcome studies (Renagel In New
Dialysis Patients (RIND) and Dialysis Clinical Outcomes
Revisited (DCOR)) showing that intake of calcium-based
binders impacts patient mortality (incident and elderly
patient populations, respectively), have been published.
These represent the first and only prospective randomized
studies ever to show a decline in mortality in hemodialysis
patients brought about by a therapeutic maneuver.
Doctors Nolan and McCarron state that the DCOR
‘authors conducted a post hoc analysis to study the effect of
patient age on the results’.9 I note that patients X65 years of
age, who had a superior survival when treated with
sevelamer, did so as the result of a pre-specified analysis in
which a significant treatment-by-age interaction was required
as a gating criteria before making inferences about age-
stratified results. While the older age group had more than
twice the mortality rate of the younger group, allowing better
precision in estimating treatment effect, there are several
reasons why sevelamer might be expected to have a greater
impact in this population. In nearly all publications
concerning vascular calcification, age is an independent
predictor of baseline calcification severity.2–4,8,10–12 Further-
more, patients with more severe calcification have the
greatest increase in calcification over time.7,8 In another
recent study, Doctors Nolan and McCarron ignore the
coronary calcification scores at the time of initiation of
dialysis, and the choice of phosphate binder, which were
found to be strong independent predictors of mortality. In
that same trial, which was an extension of the RIND trial,
patients previously assigned to sevelamer demonstrated a
significant survival benefit relative to those assigned to
calcium-based phosphate binders.13 Since these robustness
assessments were confirmatory, the finding corroborates the
body of knowledge that is accruing regarding progression of
coronary calcification in an aging hemodialysis population,
and the associated mortality risk is so high, it was deemed an
important finding to communicate to the clinical community.
The intent-to-treat analysis Doctors Nolan and
McCarron insist upon employs an entirely different data
source from that of the DCOR study, namely the Centers
for Medicare and Medicaid database. This analysis was
conducted by investigators independent from those of the
DCOR study, and will be reported by them separately.
In conclusion, it is not a matter which treatment is cheaper,
but which treatment is better for our patients’ survival. The
evidence speaks for itself; calcium is clearly linked to poor
outcomes in our patients while sevelamer is the only
phosphate binder with two prospective outcomes studies that
have demonstrated a significant survival benefit in incident
dialysis patients and in elderly prevalent dialysis patients.
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To the Editor: The paper1 raised the possibility that distal
renal tubular acidosis (dRTA) induces interstitial changes
without stone formation by unknown mechanisms. Since
proton secretion is coupled with bicarbonate secretion in
type A intercalated cells (A-IC), bicarbonate secretion into
the interstitial space should also be impaired in dRTA. In
other types of acidosis, this bicarbonate secretion is
stimulated, and the acidosis around the collecting ducts is
corrected. In dRTA, the decreased bicarbonate secretion
worsens the acidosis around the collecting duct. Since low pH
induces a variety of responses in cells, unphysiologically low
pH may cause interstitial fibrosis in dRTA.
Since the thick ascending limbs of Henle (TALHs) are
located near the collecting ducts, the TALHs are also exposed
to very low pH in dRTA. The microperfusion study indicated
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that in vitro acidosis inhibits chloride reabsorption in
TALHs.2 The decrease in chloride reabsorption in the
TALHs causes sodium loss and hypercalciuria seen in dRTA.
Another recent paper in Kidney International3 reported
that responses to furosemide are blunted in dRTA patients,
suggesting that sodium reabsorption in the TALHs is
impaired in dRTA.
Even in the same range of urine pH, the urinary
ammonium concentration of dRTA patients is much lower
than in other types of acidosis,4 and the low interstitial pH
can also explain the low NH4
þ excretion rate. NH4
þ
reabsorption in the TALHs is suppressed by the mechanisms
described above, and the low pH in the interstitial space
results in a low NH3/NH4
þ ratio and further decreases the
concentration of NH3, which diffuses into the urinary space
and is trapped as NH4
þ .
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Antiproteinuric effects of
cilnidipine
Kidney International (2008) 73, 1095; doi:10.1038/ki.2008.49
To the Editor: We read with interest the CARTER trial,1 but
we would like to see a number of issues clarified. First, does
the statement that an investigator monitored randomization
in order of the entry of the subjects in each institute mean
that allocation to randomized treatment depended on the
order of presentation of patients? Systematic rather than
random allocation might explain why the cilnidipine
compared with the amlodipine group included 19 more
patients (11.9%). Second, it is remarkable that the authors
did not give more information on the quality control of the
primary outcome measure, the urinary protein-to-creatinine
ratio (UPCR). This multicenter trial ran over 4 years. Were
the measurements done in a central laboratory? Was there
any time trend in the deviation from the UPCR standard in
the quality control program? Was the first, the second, or the
average of both UPCR measurements at entry used as the
baseline? Were single UPCR measurements sufficiently
accurate at each follow-up point, if two were required to
ascertain eligibility? What was the interassay (at baseline) and
intraassay reproducibility of the UPCR measurements? A
variability of 10% would approximate to the observed
differences. Third, although UPCR was not normally
distributed, it was statistically analyzed assuming normality.
Did the results remain consistent after transformation to
approach a normal distribution? Finally, the most important
issue, not reported in the paper, is whether the observed
changes in UPCR were due to the nominator (protein), the
denominator (creatinine), or both?
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1543–1549.
JA Staessen1
1Department of Cardiovascular Diseases, University of Leuven, Leuven,
Belgium
Correspondence: JA Staessen, Studies Coordinating Centre, Division of
Hypertension and Cardiovascular Rehabilitation, Department of
Cardiovascular Diseases, University of Leuven, Herestraat 49, Box 702,
BE-3000 Leuven, Belgium. E-mail: jan.staessen@med.kuleuven.be
Response to ‘Antiproteinuric
effects of cilnidipine’
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We are grateful for the opportunity to respond to the
comments of Dr Staessen.1 First, as mentioned in the
interventions section of the methods in our manuscript,2
randomization was done in order of the entry of the
subjects in each institute. Because only one investigator in
some institutes participated in this study, the allocation
was done at random in order that a number of the two
group subjects equal out for every 10 subjects in each
institute. Thus, even in the institute where more than 10
subjects participated, the number of subjects was often
uneven. Second, this trial was an independent study of
disinterested physicians and done as part of routine care,
and the individual payment was done by individual
patients. Thus, the measurement was not done in a central
laboratory and the quality control of primary outcome
measure was not done. We used the average of two
consecutive measured values of urinary protein-to-creati-
nine ratio (UPCR) during a 4-week observation period
before the treatment, but measured UPCR once at each
follow-up period. Despite this limitation, percentage of
changes of UPCR were consecutively (three times) lower
since early period (3 months) of the treatment in
cilnidipine group as compared with amlodipine group.
Thus, it is suggested that the add-on therapy of cilnidipine
can suppress urinary protein to a greater extent than that
of amlodipine. Third, we reanalyzed data of UPCR as
common logarithm. As a result, baseline value was not
different between cilnidipine and amlodipine groups
(mean±s.d.: 3.10±0.39 vs 3.10±0.34, NS), but logarithm
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